Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

NCT07425795 is registered in ClinicalTrials.gov with Chongqing University Cancer Hospital as lead sponsor.

NCT NCT07425795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07425795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Lead sponsor
Chongqing University Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 10, 2025
Completion date
July 31, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer (es-sclc)